AIP
PTGX icon

Arrowpoint Investment Partners’s Protagonist Therapeutics PTGX Stock Holding History

Arrowpoint Investment Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$404K Sell
3,298
-6,036
-65% -$630K 0.09% 79
2026
Q1 		$984K Buy
+9,334
New +$826K 0.87% 23

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowpoint Investment Partners's PTGX Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Protagonist Therapeutics (PTGX) stake by 65% in Q2 2026, selling an estimated $630K and leaving 3,298 shares worth $404K. The position accounts for 0.09% of the portfolio, ranked #79.

Arrowpoint Investment Partners first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $984K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Arrowpoint Investment Partners held 3,298 shares of Protagonist Therapeutics worth $404K as of Q2 2026.
  • Arrowpoint Investment Partners sold 6,036 Protagonist Therapeutics shares in Q2 2026, an estimated $630K.
  • Protagonist Therapeutics made up 0.09% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #79 holding.
  • Arrowpoint Investment Partners first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's Protagonist Therapeutics position peaked at $984K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.